Adult: For serious infections: 600 mg every 24 hours. For more severe infections: 600 mg every 12 hours. Dosing frequency may be increased depending on the severity of infection. Child: >1 month For serious infections: 10 mg/kg every 24 hours. For more severe infections: 10 mg/kg every 12 hours. Dosing frequency may be increased depending on the severity of infection. Starting age of use may vary among countries and between individual products (refer to specific product guidelines).
Intravenous Susceptible infections
Adult: For serious infections: 600-1,000 mg every 8-12 hours via slow IV infusion over at least 1 hour. Dose may be increased in more severe infections. In life-threatening infections, doses of up to 8,000 mg daily have been given. Max recommended dose: 8,000 mg daily. Child: >1 month 10-20 mg/kg daily in 2 or 3 divided doses depending on the severity of infection via slow IV infusion over at least 1 hour. Max recommended dose: 8,000 mg daily. Starting age of use may vary among countries and between individual products (refer to specific product guidelines).
Subconjunctival Susceptible infections
Adult: 75 mg as a single dose via subconjunctival inj.
What are the brands available for Lincomycin in Malaysia?
Intravenous: Solution for inj: Dilute each gram with at least 100 mL of compatible IV solution (e.g. dextrose 5% water). A 600 mg dose must be diluted in 100 mL of compatible IV solution.
Incompatibility
Incompatible with novobiocin, kanamycin, phenytoin, and alkaline preparations or agents that are unstable at low pH.
Contraindications
Hypersensitivity to lincomycin or clindamycin.
Special Precautions
Patient with history of gastrointestinal disease (particularly colitis), history of asthma, or significant allergies. Lincomycin is reserved for serious infections where less toxic antibiotics are inappropriate. Not indicated for meningitis, minor bacterial infections, or nonbacterial infections, especially URTI. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Bacterial or fungal superinfection, particularly yeasts (prolonged use); severe hypersensitivity reactions including anaphylactic reactions and severe cutaneous adverse reactions (e.g. Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis, acute generalised exanthematous pustulosis [AGEP], erythema multiforme). Blood and lymphatic system disorders: Agranulocytosis, aplastic anaemia, leucopenia, neutropenia, pancytopenia, immune thrombocytopenia. Ear and labyrinth disorders: Vertigo, tinnitus. Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal discomfort, glossitis. General disorders and administration site conditions: Inj site pain, irritation, abscess, and induration. Hepatobiliary disorders: Jaundice. Infections and infestations: Vaginal infection. Investigations: Abnormal LFTs, increased transaminases. Nervous system disorders: Dizziness, drowsiness, headache. Renal and urinary disorders: Renal impairment, oliguria, proteinuria, azotaemia. Skin and subcutaneous tissue disorders: Rash, urticaria. Vascular disorders: Hypotension, thrombophlebitis. Potentially Fatal:Clostridioides difficile-associated diarrhoea (CDAD), pseudomembranous colitis.
Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Obtain baseline LFTs and serum creatinine. Monitor CBC with differential, LFTs, and renal function (periodically during prolonged treatment). Assess for changes in bowel frequency or consistency.
Overdosage
Symptoms: Dermatitis, nephrotoxicity, hepatotoxicity, haematological abnormalities, severe diarrhoea, and pseudomembranous colitis. Rapid IV administration of large doses may cause ventricular dysrhythmias, hypotension, and cardiac arrest.
Management: Supportive treatment (e.g. respiratory and cardiac function).
Drug Interactions
May potentiate the effects of neuromuscular blocking agents. Erythromycin may reduce the therapeutic effect of lincomycin.
Action
Description: Mechanism of Action: Lincomycin is a lincosamide antibiotic that exerts bacteriostatic or bactericidal effects. It inhibits bacterial protein synthesis by binding specifically to the 23S RNA of the 50S ribosomal subunit, thereby preventing peptide bond formation and resulting in inhibition of bacterial cell growth or bacterial death. Pharmacokinetics: Absorption: Time to peak plasma concentration: 1 hour (IM). Distribution: Widely distributed into tissues, including bone and body fluids; poor diffusion into the CSF (slightly better with inflamed meninges). Crosses the placenta and enters breast milk. Metabolism: Partially metabolised in the liver. Excretion: Via urine (2-3%); bile. Serum half-life: Approx 5 hours.
Chemical Structure
Lincomycin Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3000540, Lincomycin. https://pubchem.ncbi.nlm.nih.gov/compound/Lincomycin. Accessed Sept. 26, 2025.
Storage
Store below 30°C. Protect from light and moisture. Storage recommendations may vary among countries and between individual products (refer to specific product guidelines).
J01FF02 - lincomycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.
References
Brayfield A, Cadart C (eds). Lincomycin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/09/2025.Lincomycin Hydrochloride Injection (PAI Holdings, LLC dba PAI Pharma). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/09/2025.Lincomycin Hydrochloride. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 03/09/2025.Lincomycin. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 03/09/2025.Lincomycin. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 03/09/2025.Linmycin Injection 300 mg/mL (Y.S.P. Industries [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 03/09/2025.
Sign Out
Continue with Google